OncoSec Medical Inc (ONCSQ)

[hschlauch]

Once the DNA is processed by the tumor cells and the monoclonal antibodies are produced, i.e. they exit the tumor cells, at that point they are full-fledged monoclonal antibodies capable of achieving the same role as systemically-delivered monoclonal antibodies (e.g. checkpoint inhibitors). At that point they can initiate contact with pd-1 on the surface of immune cells to block the checkpoint.

This is the same transfection process that ONCS has used to express IL-12, GP96 and FC-OX40L DNA intratumorally. After the cancer cells process the genetic material and "spit out" the product, what you get are functional IL-12, GP96 (antigen chaperones), and FC-OX40L (agonists).